<p>在全球市場應對混合經濟信號的背景下，亞洲股市表現出韌性，儘管製造業面臨持續挑戰，中國股市依然上漲。在這種環境下，內部持股比例高的成長型公司尤其吸引人，因為這通常表明對業務的強烈信心。</p>
<h3>亞洲內部持股比例高的十大成長型公司</h3>
<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>內部持股比例</strong></td>
<td><strong>盈利增長</strong></td>
</tr>
<tr>
<td>Vuno (KOSDAQ:A338220)</td>
<td>15.6%</td>
<td>113.4%</td>
</tr>
<tr>
<td>Seers Technology (KOSDAQ:A458870)</td>
<td>33.9%</td>
<td>84.6%</td>
</tr>
<tr>
<td>Oscotec (KOSDAQ:A039200)</td>
<td>12.7%</td>
<td>104.1%</td>
</tr>
<tr>
<td>Novoray (SHSE:688300)</td>
<td>23.6%</td>
<td>30.3%</td>
</tr>
<tr>
<td>Laopu Gold (SEHK:6181)</td>
<td>35.5%</td>
<td>34%</td>
</tr>
<tr>
<td>J&amp;V Energy Technology (TWSE:6869)</td>
<td>17.5%</td>
<td>24.9%</td>
</tr>
<tr>
<td>Gold Circuit Electronics (TWSE:2368)</td>
<td>31.4%</td>
<td>35.2%</td>
</tr>
<tr>
<td>Fulin Precision (SZSE:300432)</td>
<td>11.7%</td>
<td>50.7%</td>
</tr>
<tr>
<td>Ascentage Pharma Group International (SEHK:6855)</td>
<td>12.8%</td>
<td>91.9%</td>
</tr>
<tr>
<td>AprilBioLtd (KOSDAQ:A397030)</td>
<td>31%</td>
<td>87.1%</td>
</tr>
</tbody>
</table>
<p>點擊這裏查看我們快速增長的亞洲內部持股比例高的 615 只股票的完整列表。</p>
<p>下面我們重點介紹幾隻我們獨特篩選器中的最愛。</p>
<h2>美團 (SEHK:3690)</h2>
<p><strong>Simply Wall St 成長評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> 美團是一家技術驅動的零售公司，在中華人民共和國、香港、澳門、台灣及國際市場運營，市值約為 6480.7 億港元。</p>
<p><strong>運營：</strong> 公司的收入主要來自其核心本地商業部門，產生了 2646.1 億人民幣的收入，以及其新業務部門，貢獻了 958.5 億人民幣。</p>
<p><strong>內部持股比例：</strong> 11.2%</p>
<p><strong>盈利增長預測：</strong> 每年 31.7%。</p>
<p>美團的盈利預計將顯著增長，年均增長率為 31.7%，超過香港市場。儘管預測的股本回報率較低，為 18.7%，但該公司的交易價格大幅低於其估計的公允價值。最近的回購總額達到 52.2 億美元，表明對未來前景的信心，儘管近期內部購買並不顯著。預計收入年增長率為 10.9%，超過市場預期，但低於高增長基準。</p>
<ul>
<li>在這裏深入瞭解美團的具體情況，查看我們的詳細增長預測報告。</li>
<li>我們精心準備的美團估值報告暗示其股價可能低於預期。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/84d82d8f-bc2a-44fe-a39d-d6eae5c1483f/chart/earnings-and-revenue-growth?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/84d82d8f-bc2a-44fe-a39d-d6eae5c1483f/chart/earnings-and-revenue-growth"/></p>
<p>SEHK:3690 截至 2025 年 10 月的盈利和收入增長</p>
<h2>一品紅製藥集團 (SZSE:300723)</h2>
<p><strong>Simply Wall St 成長評級：</strong> ★★★★★☆</p>
<p><strong>概述：</strong> 一品紅製藥集團有限公司，市值為 266.9 億人民幣，涉及製藥產品的研發、生產和銷售，通過其子公司進行。</p>
<p><strong>運營：</strong> 一品紅製藥集團有限公司的收入來自制藥產品的研發、生產和銷售。</p>
<p><strong>內部持股比例：</strong> 19.1%</p>
<p><strong>盈利增長預測：</strong> 每年 99.5%。</p>
<p>一品紅製藥集團的收入預計將以每年 25.2% 的速度增長，超過中國市場平均 14.1% 的增速，儘管最近面臨財務挫折，包括 2025 年上半年 7354 萬人民幣的淨虧損和波動的股價。預計該公司將在三年內實現盈利，超過市場平均增長率，儘管其股本回報率仍然較低，預測為 13.1%。當前的債務水平未能得到經營現金流的良好覆蓋。</p>
<ul>
<li>通過閲讀我們的分析師估計報告，深入瞭解一品紅製藥集團的表現。</li>
<li>我們的一品紅製藥集團估值報告中的分析暗示其股價相較於估計價值被高估。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/7b915a4f-2583-49d4-85ff-04c24c5535b5/chart/ownership-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/7b915a4f-2583-49d4-85ff-04c24c5535b5/chart/ownership-breakdown"/></p>
<p>SZSE:300723 截至 2025 年 10 月的持股結構</p>
<h2>Phison Electronics (TPEX:8299)</h2>
<p><strong>Simply Wall St 成長評級：</strong> ★★★★☆☆</p>
<p><strong>概述：</strong> Phison Electronics Corp. 設計、製造並銷售閃存控制器和外圍系統應用，市值為 1712.9 億新台幣。</p>
<p><strong>運營：</strong> 該公司從其閃存控制芯片設計部門產生收入，金額為 582.4 億新台幣。</p>
<p><strong>內部持股比例：</strong> 10.9%</p>
<p><strong>盈利增長預測：</strong> 每年 25.3%。</p>
<p>儘管 Phison Electronics 的股價波動，但預計盈利和收入年增長率分別為 25.3% 和 18.4%，超過台灣市場平均水平。最近與 RedData 和 Supermicro 的戰略合作增強了其針對 AI 和高密度工作負載的存儲解決方案組合。然而，該公司的利潤率較去年有所下降，而股息仍未得到自由現金流的充分覆蓋。內部持股水平顯著，但近期缺乏購買活動。</p>
<ul>
<li>點擊探索我們在 Phison Electronics 盈利增長報告中的詳細發現。</li>
<li>我們的綜合估值報告提出 Phison Electronics 的定價可能低於其財務狀況所能證明的水平。</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f0971773-7237-44c3-9e80-ab2f47354f0d/chart/ownership-breakdown?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f0971773-7237-44c3-9e80-ab2f47354f0d/chart/ownership-breakdown"/></p>
<p>TPEX:8299 截至 2025 年 10 月的持股結構</p>
<h2>關鍵要點</h2>
<ul>
<li>在這裏調查我們 615 家快速增長的亞洲內部持股比例高的公司的完整名單。</li>
<li>想探索一些替代方案？我們發現 19 只美國股票預計明年將支付超過 6% 的股息收益率。查看完整列表，免費獲取。</li>
</ul>
<p><em>這篇來自 Simply Wall St 的文章具有一般性。<strong>我們僅基於歷史數據和分析師預測提供評論，採用無偏見的方法，我們的文章並不意圖提供財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均沒有持倉。該分析僅考慮內部人士直接持有的股票，不包括通過其他工具（如公司和/或信託實體）間接持有的股票。所有預測的收入和收益增長率均以年化（每年）增長率的形式表示，時間範圍為 1-3 年。</em></p>

一品紅

<p>亞洲股市在經濟信號混雜的情況下展現出韌性，重點關注內部持股比例高的成長型公司。值得注意的公司包括美團、 一品紅製藥集團和 Phison Electronics，它們均顯示出顯著的盈利增長預測和內部人士信心。美團的內部持股比例為 11.2%，預計年盈利增長為 31.7%。一品紅以 19.1% 的內部持股比例領先，預測增長為 99.5%。Phison Electronics 的內部持股比例為 10.9%，預計盈利增長為 25.3%。儘管面臨挑戰，這些公司在亞洲市場中反映出強大的潛力</p>

<p>As global markets navigate a landscape of mixed economic signals, Asian equities have shown resilience, with China's stock markets advancing despite ongoing challenges in the manufacturing sector. In this environment, growth companies with high insider ownership can be particularly appealing as they often indicate strong confidence from those who know the business best.</p>
<div class="lb-trans"><p>在全球市場應對混合經濟信號的背景下，亞洲股市表現出韌性，儘管製造業面臨持續挑戰，中國股市依然上漲。在這種環境下，內部持股比例高的成長型公司尤其吸引人，因為這通常表明對業務的強烈信心。</p>
</div><h3>Top 10 Growth Companies With High Insider Ownership In Asia</h3>
<div class="lb-trans"><h3>亞洲內部持股比例高的十大成長型公司</h3>
</div><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Name</strong></td>
<td><strong>Insider Ownership</strong></td>
<td><strong>Earnings Growth</strong></td>
</tr>
<tr>
<td>Vuno (KOSDAQ:A338220)</td>
<td>15.6%</td>
<td>113.4%</td>
</tr>
<tr>
<td>Seers Technology (KOSDAQ:A458870)</td>
<td>33.9%</td>
<td>84.6%</td>
</tr>
<tr>
<td>Oscotec (KOSDAQ:A039200)</td>
<td>12.7%</td>
<td>104.1%</td>
</tr>
<tr>
<td>Novoray (SHSE:688300)</td>
<td>23.6%</td>
<td>30.3%</td>
</tr>
<tr>
<td>Laopu Gold (SEHK:6181)</td>
<td>35.5%</td>
<td>34%</td>
</tr>
<tr>
<td>J&amp;V Energy Technology (TWSE:6869)</td>
<td>17.5%</td>
<td>24.9%</td>
</tr>
<tr>
<td>Gold Circuit Electronics (TWSE:2368)</td>
<td>31.4%</td>
<td>35.2%</td>
</tr>
<tr>
<td>Fulin Precision (SZSE:300432)</td>
<td>11.7%</td>
<td>50.7%</td>
</tr>
<tr>
<td>Ascentage Pharma Group International (SEHK:6855)</td>
<td>12.8%</td>
<td>91.9%</td>
</tr>
<tr>
<td>AprilBioLtd (KOSDAQ:A397030)</td>
<td>31%</td>
<td>87.1%</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>名稱</strong></td>
<td><strong>內部持股比例</strong></td>
<td><strong>盈利增長</strong></td>
</tr>
<tr>
<td>Vuno (KOSDAQ:A338220)</td>
<td>15.6%</td>
<td>113.4%</td>
</tr>
<tr>
<td>Seers Technology (KOSDAQ:A458870)</td>
<td>33.9%</td>
<td>84.6%</td>
</tr>
<tr>
<td>Oscotec (KOSDAQ:A039200)</td>
<td>12.7%</td>
<td>104.1%</td>
</tr>
<tr>
<td>Novoray (SHSE:688300)</td>
<td>23.6%</td>
<td>30.3%</td>
</tr>
<tr>
<td>Laopu Gold (SEHK:6181)</td>
<td>35.5%</td>
<td>34%</td>
</tr>
<tr>
<td>J&amp;V Energy Technology (TWSE:6869)</td>
<td>17.5%</td>
<td>24.9%</td>
</tr>
<tr>
<td>Gold Circuit Electronics (TWSE:2368)</td>
<td>31.4%</td>
<td>35.2%</td>
</tr>
<tr>
<td>Fulin Precision (SZSE:300432)</td>
<td>11.7%</td>
<td>50.7%</td>
</tr>
<tr>
<td>Ascentage Pharma Group International (SEHK:6855)</td>
<td>12.8%</td>
<td>91.9%</td>
</tr>
<tr>
<td>AprilBioLtd (KOSDAQ:A397030)</td>
<td>31%</td>
<td>87.1%</td>
</tr>
</tbody>
</table>
</div><p>Click here to see the full list of 615 stocks from our Fast Growing Asian Companies With High Insider Ownership screener.</p>
<div class="lb-trans"><p>點擊這裏查看我們快速增長的亞洲內部持股比例高的 615 只股票的完整列表。</p>
</div><p>Below we spotlight a couple of our favorites from our exclusive screener.</p>
<div class="lb-trans"><p>下面我們重點介紹幾隻我們獨特篩選器中的最愛。</p>
</div><h2>Meituan (SEHK:3690)</h2>
<div class="lb-trans"><h2>美團 (SEHK:3690)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成長評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Meituan is a technology-driven retail company operating in the People's Republic of China, Hong Kong, Macao, Taiwan, and internationally with a market cap of approximately HK$648.07 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> 美團是一家技術驅動的零售公司，在中華人民共和國、香港、澳門、台灣及國際市場運營，市值約為 6480.7 億港元。</p>
</div><p><strong>Operations:</strong> The company's revenue primarily comes from its Core Local Commerce segment, generating CN¥264.61 billion, and its New Initiatives segment, contributing CN¥95.85 billion.</p>
<div class="lb-trans"><p><strong>運營：</strong> 公司的收入主要來自其核心本地商業部門，產生了 2646.1 億人民幣的收入，以及其新業務部門，貢獻了 958.5 億人民幣。</p>
</div><p><strong>Insider Ownership:</strong> 11.2%</p>
<div class="lb-trans"><p><strong>內部持股比例：</strong> 11.2%</p>
</div><p><strong>Earnings Growth Forecast:</strong> 31.7% p.a.</p>
<div class="lb-trans"><p><strong>盈利增長預測：</strong> 每年 31.7%。</p>
</div><p>Meituan's earnings are expected to grow significantly at 31.7% annually, outpacing the Hong Kong market. Despite a lower Return on Equity forecast of 18.7%, the company trades at a substantial discount to its estimated fair value. Recent buybacks totaling $5.22 billion indicate confidence in future prospects, although insider buying hasn't been substantial recently. Revenue growth is forecasted at 10.9% per year, surpassing market expectations but below high-growth benchmarks.</p>
<div class="lb-trans"><p>美團的盈利預計將顯著增長，年均增長率為 31.7%，超過香港市場。儘管預測的股本回報率較低，為 18.7%，但該公司的交易價格大幅低於其估計的公允價值。最近的回購總額達到 52.2 億美元，表明對未來前景的信心，儘管近期內部購買並不顯著。預計收入年增長率為 10.9%，超過市場預期，但低於高增長基準。</p>
</div><ul>
<li>Dive into the specifics of Meituan here with our thorough growth forecast report.</li>
<li>Our expertly prepared valuation report Meituan implies its share price may be lower than expected.</li>
</ul>
<div class="lb-trans"><ul>
<li>在這裏深入瞭解美團的具體情況，查看我們的詳細增長預測報告。</li>
<li>我們精心準備的美團估值報告暗示其股價可能低於預期。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/84d82d8f-bc2a-44fe-a39d-d6eae5c1483f/chart/earnings-and-revenue-growth" alt="" original-src="https://images.simplywall.st/company/84d82d8f-bc2a-44fe-a39d-d6eae5c1483f/chart/earnings-and-revenue-growth"/></p>
<p>SEHK:3690 Earnings and Revenue Growth as at Oct 2025</p>
<div class="lb-trans"><p>SEHK:3690 截至 2025 年 10 月的盈利和收入增長</p>
</div><h2>ApicHope Pharmaceutical Group (SZSE:300723)</h2>
<div class="lb-trans"><h2>一品紅製藥集團 (SZSE:300723)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★★☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成長評級：</strong> ★★★★★☆</p>
</div><p><strong>Overview:</strong> ApicHope Pharmaceutical Group Co., Ltd., with a market cap of CN¥26.69 billion, is involved in the research and development, production, and sale of pharmaceutical drugs through its subsidiaries.</p>
<div class="lb-trans"><p><strong>概述：</strong> 一品紅製藥集團有限公司，市值為 266.9 億人民幣，涉及製藥產品的研發、生產和銷售，通過其子公司進行。</p>
</div><p><strong>Operations:</strong> ApicHope Pharmaceutical Group Co., Ltd. generates its revenue from the research, development, production, and sale of pharmaceutical drugs.</p>
<div class="lb-trans"><p><strong>運營：</strong> 一品紅製藥集團有限公司的收入來自制藥產品的研發、生產和銷售。</p>
</div><p><strong>Insider Ownership:</strong> 19.1%</p>
<div class="lb-trans"><p><strong>內部持股比例：</strong> 19.1%</p>
</div><p><strong>Earnings Growth Forecast:</strong> 99.5% p.a.</p>
<div class="lb-trans"><p><strong>盈利增長預測：</strong> 每年 99.5%。</p>
</div><p>ApicHope Pharmaceutical Group's revenue is forecast to grow at 25.2% annually, outpacing the Chinese market average of 14.1%, despite recent financial setbacks including a net loss of CNY 73.54 million for H1 2025 and volatile share prices. The company is expected to become profitable within three years, surpassing average market growth rates, although its Return on Equity remains low at a forecasted 13.1%. Current debt levels are not well covered by operating cash flow.</p>
<div class="lb-trans"><p>一品紅製藥集團的收入預計將以每年 25.2% 的速度增長，超過中國市場平均 14.1% 的增速，儘管最近面臨財務挫折，包括 2025 年上半年 7354 萬人民幣的淨虧損和波動的股價。預計該公司將在三年內實現盈利，超過市場平均增長率，儘管其股本回報率仍然較低，預測為 13.1%。當前的債務水平未能得到經營現金流的良好覆蓋。</p>
</div><ul>
<li>Get an in-depth perspective on ApicHope Pharmaceutical Group's performance by reading our analyst estimates report here.</li>
<li>The analysis detailed in our ApicHope Pharmaceutical Group valuation report hints at an inflated share price compared to its estimated value.</li>
</ul>
<div class="lb-trans"><ul>
<li>通過閲讀我們的分析師估計報告，深入瞭解一品紅製藥集團的表現。</li>
<li>我們的一品紅製藥集團估值報告中的分析暗示其股價相較於估計價值被高估。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/7b915a4f-2583-49d4-85ff-04c24c5535b5/chart/ownership-breakdown" alt="" original-src="https://images.simplywall.st/company/7b915a4f-2583-49d4-85ff-04c24c5535b5/chart/ownership-breakdown"/></p>
<p>SZSE:300723 Ownership Breakdown as at Oct 2025</p>
<div class="lb-trans"><p>SZSE:300723 截至 2025 年 10 月的持股結構</p>
</div><h2>Phison Electronics (TPEX:8299)</h2>
<div class="lb-trans"><h2>Phison Electronics (TPEX:8299)</h2>
</div><p><strong>Simply Wall St Growth Rating:</strong> ★★★★☆☆</p>
<div class="lb-trans"><p><strong>Simply Wall St 成長評級：</strong> ★★★★☆☆</p>
</div><p><strong>Overview:</strong> Phison Electronics Corp. designs, manufactures, and sells flash memory controllers and peripheral system applications globally, with a market cap of NT$171.29 billion.</p>
<div class="lb-trans"><p><strong>概述：</strong> Phison Electronics Corp. 設計、製造並銷售閃存控制器和外圍系統應用，市值為 1712.9 億新台幣。</p>
</div><p><strong>Operations:</strong> The company generates revenue from its flash memory control chip design segment, amounting to NT$58.24 billion.</p>
<div class="lb-trans"><p><strong>運營：</strong> 該公司從其閃存控制芯片設計部門產生收入，金額為 582.4 億新台幣。</p>
</div><p><strong>Insider Ownership:</strong> 10.9%</p>
<div class="lb-trans"><p><strong>內部持股比例：</strong> 10.9%</p>
</div><p><strong>Earnings Growth Forecast:</strong> 25.3% p.a.</p>
<div class="lb-trans"><p><strong>盈利增長預測：</strong> 每年 25.3%。</p>
</div><p>Phison Electronics, despite a volatile share price, is positioned for growth with forecasted earnings and revenue increases of 25.3% and 18.4% annually, respectively, outpacing Taiwan's market averages. Recent strategic partnerships with RedData and Supermicro enhance its storage solutions portfolio for AI and high-density workloads. However, the company's profit margins have declined from last year while dividends remain inadequately covered by free cash flows. Insider ownership levels are significant but lack recent buying activity.</p>
<div class="lb-trans"><p>儘管 Phison Electronics 的股價波動，但預計盈利和收入年增長率分別為 25.3% 和 18.4%，超過台灣市場平均水平。最近與 RedData 和 Supermicro 的戰略合作增強了其針對 AI 和高密度工作負載的存儲解決方案組合。然而，該公司的利潤率較去年有所下降，而股息仍未得到自由現金流的充分覆蓋。內部持股水平顯著，但近期缺乏購買活動。</p>
</div><ul>
<li>Click to explore a detailed breakdown of our findings in Phison Electronics' earnings growth report.</li>
<li>Our comprehensive valuation report raises the possibility that Phison Electronics is priced lower than what may be justified by its financials.</li>
</ul>
<div class="lb-trans"><ul>
<li>點擊探索我們在 Phison Electronics 盈利增長報告中的詳細發現。</li>
<li>我們的綜合估值報告提出 Phison Electronics 的定價可能低於其財務狀況所能證明的水平。</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/f0971773-7237-44c3-9e80-ab2f47354f0d/chart/ownership-breakdown" alt="" original-src="https://images.simplywall.st/company/f0971773-7237-44c3-9e80-ab2f47354f0d/chart/ownership-breakdown"/></p>
<p>TPEX:8299 Ownership Breakdown as at Oct 2025</p>
<div class="lb-trans"><p>TPEX:8299 截至 2025 年 10 月的持股結構</p>
</div><h2>Key Takeaways</h2>
<div class="lb-trans"><h2>關鍵要點</h2>
</div><ul>
<li>Investigate our full lineup of 615 Fast Growing Asian Companies With High Insider Ownership right here.</li>
<li>Want To Explore Some Alternatives? We've found 19 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free.</li>
</ul>
<div class="lb-trans"><ul>
<li>在這裏調查我們 615 家快速增長的亞洲內部持股比例高的公司的完整名單。</li>
<li>想探索一些替代方案？我們發現 19 只美國股票預計明年將支付超過 6% 的股息收益率。查看完整列表，免費獲取。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.</em></p>
<div class="lb-trans"><p><em>這篇來自 Simply Wall St 的文章具有一般性。<strong>我們僅基於歷史數據和分析師預測提供評論，採用無偏見的方法，我們的文章並不意圖提供財務建議。</strong> 它不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們的目標是為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中均沒有持倉。該分析僅考慮內部人士直接持有的股票，不包括通過其他工具（如公司和/或信託實體）間接持有的股票。所有預測的收入和收益增長率均以年化（每年）增長率的形式表示，時間範圍為 1-3 年。</em></p>
</div>

3 只亞洲成長股受到內部人士的強烈信心支持